In the BioHarmony Drug Report Database
Esmolol
Brevibloc, Esmolol (esmolol) is a small molecule pharmaceutical. Esmolol was first approved as Brevibloc on 1988-08-15. It is used to treat angina pectoris, heart failure, hypertension, myocardial infarction, and supraventricular tachycardia amongst others in the USA. The pharmaceutical is active against beta-1 adrenergic receptor. Brevibloc’s patents are valid until 2033-03-15 (FDA).
Trade Name
|
Brevibloc, Esmolol |
|---|---|
Common Name
|
esmolol |
ChEMBL ID
|
CHEMBL768 |
Indication
|
angina pectoris, heart failure, hypertension, myocardial infarction, supraventricular tachycardia, ventricular fibrillation, ventricular tachycardia |
Drug Class
|
Beta-blockers (propranolol type) |
Image (chem structure or protein)